Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
29,36 USD | +1,87% | -1,04% | +272,12% |
Vakgebied
Aantal werknemers: 45
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 15-03-22 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 22-09-23 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-20 |
Wendy Pang
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-20 |
Edwin Tucker
CTO | Chief Tech/Sci/R&D Officer | 52 | 12-06-23 |
Jeet Mahal
COO | Chief Operating Officer | 52 | 01-12-19 |
Matthew Ford
HRO | Human Resources Officer | - | 13-04-23 |
David Hinds
PRN | Corporate Officer/Principal | - | 10-04-23 |
Patricia Carlos
LAW | General Counsel | - | 02-08-23 |
Arjun Agarwal
AUD | Comptroller/Controller/Auditor | - | 01-01-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 15-03-22 |
Thomas Wiggans
CHM | Chairman | 72 | 01/11 |
Kurt von Emster
BRD | Director/Board Member | 56 | 24-09-21 |
Scott Brun
BRD | Director/Board Member | 56 | 20-06-23 |
Vishal Kapoor
BRD | Director/Board Member | 48 | 16-02-23 |
Christian Nolet
BRD | Director/Board Member | 67 | 24-09-21 |
Anna Phil
BRD | Director/Board Member | 36 | 24-09-19 |
Judith Shizuru
FOU | Founder | 68 | 01-03-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 15 063 896 | 13 892 140 ( 92,22 %) | 0 | 92,22 % |
Bedrijfsgegevens
Jasper Therapeutics, Inc.
2200 Bridge Parkway Suite 102
94065, Redwood City
+
http://www.jaspertherapeutics.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+272,12% | 442 mln. | |
+33,46% | 701 mld. | |
+26,24% | 570 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 322 mld. | |
+0,74% | 209 mld. | |
+2,95% | 212 mld. | |
-6,05% | 205 mld. | |
-3,61% | 157 mld. |
- Beurs
- Aandelen
- Aandeel Jasper Therapeutics, Inc. - Nasdaq
- Onderneming Jasper Therapeutics, Inc.